Common viruses that live in our blood and saliva are affected by a person’s genes, age, sex, time of day and season, and one virus (Epstein–Barr virus) at higher levels seems to raise the risk of a certain blood cancer but not multiple sclerosis.
The study measured DNA from 31 common viruses in blood and saliva from hundreds of thousands of people and found that how much virus is present (viral load) changes a lot with age, time of day, and season—like how pollen levels rise and fall.Men tended to have higher amounts of most of these viruses than women, showing that sex can affect how the body controls ongoing viral infections.Differences in people’s genes at many places in the genome were linked to how much of seven specific viruses were present; the strongest links were near the MHC region, which helps the immune system recognize infected cells.Specific gene changes involved proteins that help prepare bits of virus for the immune system to see (for example ERAP1 and ERAP2), which is like the body putting viral ‘flags’ on cells for inspection.Using genetic methods that test cause-and-effect, higher long-term EBV DNA levels were linked to a higher risk of Hodgkin’s lymphoma (a type of blood cancer), but these analyses did not support a direct genetic cause for multiple sclerosis.
People with MS and their caregivers should care because the study helps separate two ideas: having EBV in the body and having an immune reaction to EBV. This matters because MS has been tied to EBV before, but the study suggests it’s more about the immune response than just how much EBV is present.If you worry that having more EBV DNA would directly cause MS, this study suggests that higher EBV levels are not shown to directly increase MS risk—so monitoring EBV load alone may not predict MS.Patients concerned about cancer risk should know that very high long-term EBV DNA levels relate to a greater chance of Hodgkin’s lymphoma; this is like watching a warning light that is linked to one specific outcome, not every illness.Clinicians and caregivers might use this information to focus on immune system behavior (how the body reacts to viruses) rather than just viral amounts when thinking about autoimmune risks like MS.People who are tracking symptoms, treatments, or immune changes (for example when starting immune-suppressing drugs) should communicate with their care team about virus monitoring and what it could or could not mean for their MS care.
The study looked at large groups of people and found links, but links do not always prove direct cause-and-effect for all outcomes; only EBV and Hodgkin’s lymphoma had stronger evidence suggesting a causal effect.Measurements came from blood and saliva DNA at particular times; because viral levels change with time of day, season, and age, a single test may not represent long-term levels—think of it like a single weather reading versus long-term climate.The genetic findings point to how the immune system and genes affect viral levels, but they don’t mean everyone with certain gene types will get a disease; other factors like environment, treatments, and overall health also matter.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds a brain‑seeking CD4 killer cell tied to MS and CMV exposure that may resist some treatme
Read More5/1/2026
Study shows after optic neuritis the ganglion cell layer (GCL) loses more tissue than the inner plex
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds specific spinal fluid proteins tied to early nerve damage in active MS, highlighting imm
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Nature often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.